BR112022017758A2 - Composições farmacêuticas de um inibidor de quinase - Google Patents

Composições farmacêuticas de um inibidor de quinase

Info

Publication number
BR112022017758A2
BR112022017758A2 BR112022017758A BR112022017758A BR112022017758A2 BR 112022017758 A2 BR112022017758 A2 BR 112022017758A2 BR 112022017758 A BR112022017758 A BR 112022017758A BR 112022017758 A BR112022017758 A BR 112022017758A BR 112022017758 A2 BR112022017758 A2 BR 112022017758A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
kinase inhibitor
inhibitor
kinase
cyclopropanesulfonamide
Prior art date
Application number
BR112022017758A
Other languages
English (en)
Inventor
Dargelas Frederic
Koistinen Piritta
Leimu Laura
Matilainen Laura
Metsälä Henri
Shevchenko Anna
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of BR112022017758A2 publication Critical patent/BR112022017758A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS DE UM INIBIDOR DE QUINASE. A presente invenção se refere a composições farmacêuticas compreendendo sal de cloridrato de N-(2',4'-difluoro-5-(5-(1-metil-1H-pirazol-4-il)-1H-benzo[d]imidazol-1-il)-[1,1'-bifenil]-3-il)ciclopropanossulfonamida (I) como um ingrediente ativo e copovidona como um excipiente. O Composto (I) é um inibidor seletivo de famílias de quinase FGFR/VEGFR e é útil no tratamento de câncer.
BR112022017758A 2020-03-05 2021-03-05 Composições farmacêuticas de um inibidor de quinase BR112022017758A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20205233 2020-03-05
PCT/FI2021/050162 WO2021176146A1 (en) 2020-03-05 2021-03-05 Pharmaceutical compositions of a kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112022017758A2 true BR112022017758A2 (pt) 2022-11-29

Family

ID=75108350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017758A BR112022017758A2 (pt) 2020-03-05 2021-03-05 Composições farmacêuticas de um inibidor de quinase

Country Status (9)

Country Link
US (1) US20230119355A1 (pt)
EP (1) EP4114359A1 (pt)
JP (1) JP2023516358A (pt)
KR (1) KR20220149744A (pt)
CN (1) CN115605186A (pt)
BR (1) BR112022017758A2 (pt)
CA (1) CA3170261A1 (pt)
MX (1) MX2022011058A (pt)
WO (1) WO2021176146A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024246852A2 (en) * 2023-06-01 2024-12-05 Aurigene Oncology Limited Method of treating fibrotic diseases using protein kinase inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
WO2014063101A1 (en) * 2012-10-18 2014-04-24 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP7205018B2 (ja) * 2017-03-23 2023-01-17 アウリジーン ディスカバリー テクノロジーズ リミテッド スルホンアミド構造のキナーゼ阻害剤の製造方法
AR111960A1 (es) * 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MY203097A (en) * 2018-09-06 2024-06-09 Aurigene Oncology Ltd Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor

Also Published As

Publication number Publication date
WO2021176146A1 (en) 2021-09-10
CA3170261A1 (en) 2021-09-10
US20230119355A1 (en) 2023-04-20
CN115605186A (zh) 2023-01-13
EP4114359A1 (en) 2023-01-11
MX2022011058A (es) 2022-12-13
KR20220149744A (ko) 2022-11-08
JP2023516358A (ja) 2023-04-19

Similar Documents

Publication Publication Date Title
AU2005210004B2 (en) Novel inhibitors of glutaminyl cyclase
JOP20230113A1 (ar) مشتقات ثلاثية الكربوكساميد كمثبطات prmt5
JOP20220247A1 (ar) مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k
CR20230517A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
SA522432955B1 (ar) Kras g12c مثبطات
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
DOP2010000310A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
NO20071314L (no) Peptidiske vasopressinreseptoragonister
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
FI3546462T3 (fi) Uusi oksoisokinoliinijohdannainen
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
JOP20240055A1 (ar) عقار أولي من مشتقات بيروليدون كمنشط جلوكوكيناز
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
BR112022017758A2 (pt) Composições farmacêuticas de um inibidor de quinase
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
EA202190696A1 (ru) Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]